Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,049,942
  • Shares Outstanding, K 94,546
  • Annual Sales, $ 1,046 M
  • Annual Income, $ 407,300 K
  • 60-Month Beta 0.73
  • Price/Sales 8.71
  • Price/Cash Flow 20.59
  • Price/Book 7.09
Trade NBIX with:

Options Overview

Details
  • Implied Volatility 39.86%
  • Historical Volatility 24.52%
  • IV Percentile 13%
  • IV Rank 26.36%
  • IV High 62.16% on 10/20/20
  • IV Low 31.88% on 05/26/21
  • Put/Call Vol Ratio 2.04
  • Today's Volume 283
  • Volume Avg (30-Day) 362
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 5,622
  • Open Int (30-Day) 5,667

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.50
  • Number of Estimates 11
  • High Estimate 0.81
  • Low Estimate 0.04
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +180.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.26 +7.23%
on 08/17/21
98.20 -2.53%
on 09/13/21
+5.54 (+6.14%)
since 08/16/21
3-Month
84.77 +12.92%
on 08/12/21
103.72 -7.71%
on 06/21/21
-2.87 (-2.91%)
since 06/16/21
52-Week
84.77 +12.92%
on 08/12/21
120.27 -20.41%
on 01/25/21
-5.50 (-5.43%)
since 09/16/20

Most Recent Stories

More News
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the...

NBIX : 95.72 (-0.64%)
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq:...

XENE : 17.00 (-1.62%)
NBIX : 95.72 (-0.64%)
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences:

NBIX : 95.72 (-0.64%)
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the , today announced the completion of patient enrollment for its Phase 3 () clinical study evaluating the efficacy,...

NBIX : 95.72 (-0.64%)
Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.31% and 5.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NBIX : 95.72 (-0.64%)
Neurocrine: Q2 Earnings Snapshot

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Tuesday reported second-quarter profit of $42.3 million.

NBIX : 95.72 (-0.64%)
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2021.

NBIX : 95.72 (-0.64%)
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on . Neurocrine will then host a conference...

NBIX : 95.72 (-0.64%)
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that , Chief Business Development and Strategy Officer, will participate in a neuropsychology-focused panel discussion at the...

NBIX : 95.72 (-0.64%)
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42 Annual Global Healthcare Conference at , June 8, 2021. , Chief Executive Officer, will present at the...

NBIX : 95.72 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 99.66
2nd Resistance Point 98.03
1st Resistance Point 96.87
Last Price 95.72
1st Support Level 94.09
2nd Support Level 92.46
3rd Support Level 91.30

See More

52-Week High 120.27
Fibonacci 61.8% 106.71
Fibonacci 50% 102.52
Fibonacci 38.2% 98.33
Last Price 95.72
52-Week Low 84.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar